Flex Pharma to cut two trials, reduce headcount and explore merger options

By Flora Southey contact

- Last updated on GMT

(Image: Getty/Tashatuvango)
(Image: Getty/Tashatuvango)
Oral tolerability concerns have prompted the US biotech to close Ph II clinical trial investigations of FLX-787 in amyotrophic lateral sclerosis (ALS) and Charcot-Marie-Tooth (CMT).

“Recent observations of oral intolerability at the current dose and formulation, in a subset of patients, in both studies, indicate that more formulation and dose-ranging studies are required, which is challenging for the Company based upon our current resources,” ​said CEO Bill McVicar in a statement​.

The firm will continue its investigation of FLX-787 in patients with dysphagia (difficulty swallowing).

In a Securities and Exchange Commission (SEC) filing​, Flex Pharma also outlined its intention to reduce headcount and explore the possibility of a sale or merger: “…The company plans to reduce its workforce by approximately 60%, with the majority of the reduction in personnel expected to be completed by June 30, 2018.” ​ 

The firm anticipates the restructure to cost between $800k (€676k) and $1.1m.

In addition, the filing states that Flex Pharma’s “board and management team have initiated a process to explore a range of strategic alternatives for enhancing stockholder value, including the potential sale or merger of the company.”

Flex Pharma did not respond to a request for comment.

Earlier this year​, Takeda Pharmaceuticals​ also announced its intention to target amyotrophic lateral sclerosis through a nucleic acid-focused collaboration with Wave Life Sciences.

Related news

Related products

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers